BSXBoston Scientific CorporationRunning, no new patients
TheraSphere With Durvalumab and Tremelimumab for HCC
Hepatocellular Carcinoma
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.6
Announced layoffs or restructuring
Since Jul 27, 2026 · was worth 15, fading over time
Worry score5
Score over time
- Stage
- Phase 2
- Patients
- 100 (planned)
- Started
- Nov 3, 2023
- Main results expected
- Jun 2027
- Fully finished
- Jun 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR)
Measured over: Start of Treatment (Day 1) up to subsequent anti-cancer therapy, participant's death, opposition to data collection, lost to follow-up, or study termination (18 months after the last patient is treated)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- layoffs: base 15, now 4.6, since 2026-07-27, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT05063565 · record last updated 2026-10-30 · checked 2026-11-09 15:47 UTC